Abstract
Introduction: Migraine is a common neurological disorder, treated with antimigraine drugs such as ergotamine and triptans. However, the prescription of these medications can lead to potential pharmacological interactions and adverse events, especially when combined with other drugs.
Materials and methods: A cross-sectional study with convenience sampling was conducted using data from a pharmaceutical provider's database. Data collection was performed using a content form in Microsoft Excel, and analysis was carried out using Jamovi 2.2.5.
Results: 44.388 patients with dispensation of ergotamine and triptans were identified, 2.89% exhibited potential pharmacological interactions. The most common medication combinations involved in these potential pharmacological interactions were ergotamine-sumatriptan, ergotamine-ketoconazole, and ergotamine-azithromycin.
Discussion: The low prevalence of these interactions in the total population is estimated to be due to the fact that the medications causing these potential interactions are primarily used in the treatment of acute pathologies.
Conclusions: Pharmacological interactions related to ergotamine appear to be more frequent. This emphasizes the importance of carefully evaluating the prescription and dispensation of ergotamine to minimize associated risks.
References
Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. https://doi.org/10.1186/s10194-022-01402-2
Silva Sieger FA, Díaz-Silva GA, Ardila M, Saavedra-Chacón MF. La migraña: sobreconocido impacto en la población. Acta Neurol Colomb. 2012;28(3):143-51.
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18. https://doi.org/10.1111/head.13456
Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-39. https://doi.org/10.1111/head.14153
Micromedex. MDX Pharmaceutical Knowledge [internet]. Micromdex [citado 2023 nov. 9]. Disponible en: https://www.micromedexsolutions.com
Rolan P. Drug interactions with triptans. CNS Drugs. 2012;26(11):949-57. https://doi.org/10.1007/s40263-012-0002-5
Volcy Gómez M. Triptanes. Acta Neurol Colomb. 2008;24:S140-52. https://actaneurologica.com/index.php/anc/article/view/1564/1305
Ministerio de Salud y Protección Social. Ciclo de vida [internet]. Minsalud. [citado 2023 nov. 9]. Disponible en: https://www.minsalud.gov.co/proteccionsocial/Paginas/ciclovida.aspx
Sánchez-Pérez H, Ramírez-Rosillo FJ, Carrillo-Esper R. Polifarmacia en el adulto mayor. Consideraciones en el perioperatorio. Rev Mex Anestesiol. 2022;45(1):40-7. https://doi.org/10.35366/102902
McFarland HM. Identification and management of drug interactions [internet]. Medscape. [citado 2023 nov. 9]. Disponible en: https://www.medscape.org/viewarticle/418376?icd=login_success_email_match_norm
Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME. Patterns of pharmacological treatment of patients with migraine, tension-type headache, and cluster headache in a large group of patients in Colombia, 2019. Int Clin Psychopharmacol. 2020;35(5):279-84. https://doi.org/10.1097/YIC.0000000000000319
Donnet A, Braunstein D, Pradel V, Sciortino V, Allaria-Lapierre V, Micallef J, et al. Ergot use and overuse: a pharmacoepidemiology retrospective cohort study. Headache. 2016;56(3):547-54. http://dx.doi.org/10.1111/head.12776
Micromedex. Ketoconazole [internet]. Micromedex. [citado 2023 nov. 9]. Disponible en: https://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deeplink&Searchterm=ketoconazole#
Srisuma S, Lavonas EJ, Wananukul W. Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors. Clin Toxicol. 2014;52(7):674-7. https://doi.org/10.3109/15563650.2014.933230
Marín-Rincón HA, Machado-Duque ME, Machado-Alba JE. Para qué indicaciones se están utilizando los antidepresivos en adultos de Colombia. Rev Colomb Psiquiatr. 2022;51(3):192-8. https://doi.org/10.1016/j.rcp.2020.11.004
Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache. 2003;43(1):44-8. http://dx.doi.org/10.1046/j.1526-4610.2003.03007.x
Ministerio de Salud y Protección Social. Minsalud, comprometido con la salud mental de los colombianos [internet]. Minsalud [citado 2023 nov. 10]. Disponible en: https://www.minsalud.gov.co/paginas/minsalud-comprometido-con-la-salud-mental-de-los-colombianos.aspx
Piccinni C, Cevoli S, Ronconi G, Dondi L, Calabria S, Pedrini A, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74. https://doi.org/10.1186/s10194-019-1027-7
Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol. 2018;75(5):566-72. https://doi.org/10.1001/jamaneurol.2017.5144
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.